These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19150551)

  • 1. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed.
    Morales A; Phadke K; Steinhoff G
    J Urol; 2009 Mar; 181(3):1040-5. PubMed ID: 19150551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.
    Morales A; Chin JL; Ramsey EW
    J Urol; 2001 Nov; 166(5):1633-7; discussion 1637-8. PubMed ID: 11586191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fate of bacillus Calmette-Guerin after intravesical instillation.
    Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
    J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
    Mugiya S; Ozono S; Nagata M; Takayama T; Ito T; Maruyama S; Hadano S; Nagae H
    Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin.
    Sidi AA; Ohana P; Benjamin S; Shalev M; Ransom JH; Lamm D; Hochberg A; Leibovitch I
    J Urol; 2008 Dec; 180(6):2379-83. PubMed ID: 18950807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
    Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
    Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder.
    Koga H; Kuroda M; Kudo S; Yamaguchi A; Usami M; Suzuki T; Naito S
    Int J Urol; 2005 Feb; 12(2):145-51. PubMed ID: 15733108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin?
    Propert KJ; Mayer R; Nickel JC; Payne CK; Peters KM; Teal V; Burks D; Kusek JW; Nyberg LM; Foster HE;
    J Urol; 2007 Sep; 178(3 Pt 1):886-90. PubMed ID: 17631335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
    Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
    Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
    Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
    van der Heijden AG; Moonen PM; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Barten EJ; Puri R; van Kalken CK; Witjes JA
    J Urol; 2006 Oct; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
    Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
    Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
    Bisiaux A; Thiounn N; Timsit MO; Eladaoui A; Chang HH; Mapes J; Mogenet A; Bresson JL; Prié D; Béchet S; Baron C; Sadorge C; Thomas S; Albert EB; Albert PS; Albert ML
    J Urol; 2009 Apr; 181(4):1571-80. PubMed ID: 19230924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.